Articles tagged with Cancer Treatments
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
Researchers at UMass Amherst create a platform technology to target and destroy cancer-causing proteins, offering tailored treatments for specific cancers. A separate approach delivers fully functional proteins to reprogram cancerous cells, restoring their normal function.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
Large language models (LLMs) provide treatment recommendations for early-stage hepatocellular carcinoma (HCC) that align with clinical guidelines. However, their performance is limited in late-stage disease, where they prioritize tumor factors over liver function. LLMs should be used as a supplement to clinical expertise.
A machine learning model has identified the most important drivers of cancer survival in nearly all countries, highlighting factors such as national wealth, access to radiotherapy and universal health coverage. The model provides data-driven roadmaps for policymakers to prioritize resources and close survival gaps.
Researchers developed an algorithm using whole-genome sequencing to detect homologous recombination deficiency, a type of DNA-repair defect vulnerable to PARP inhibitors. The approach identified genetic mutations beyond BRCA1 and BRCA2, promising more accurate patient selection for cancer treatment.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
A Mass General Brigham study identifies new mutations that emerge in tumor cells following treatment, driving resistance in patients with different types of cancer. The researchers found two main categories of mutations: those impairing p53 function and others disrupting drug binding, highlighting a path forward for overcoming resistance.
Researchers at University of British Columbia have successfully grown specialized immune cells called helper T cells from stem cells in a controlled laboratory setting. This breakthrough could lead to more accessible and effective off-the-shelf treatments for various conditions, including cancer, autoimmune disorders, and infectious di...
The Mount Sinai Health System has launched an AI-powered clinical trial-matching platform, PRISM, to help connect patients with life-saving trials. The platform uses machine learning to match patients with trials based on their electronic health records and diagnosis.
The collaboration aims to integrate AI-powered analytics with clinical expertise to accelerate data-driven cancer care. MD Anderson researchers will leverage SOPHIAs AI technologies to develop bioinformatics pipelines for rapid RNA-sequencing data interpretation.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Two studies found that elevated bacteria levels in tumors weaken immune response, driving resistance to immunotherapy. Researchers are now exploring how to identify patients most likely to benefit from immunotherapy and develop targeted interventions to restore its effectiveness.
Researchers create a novel mathematical framework to control biological noise, enabling precise single-cell control. The 'Noise Robust Perfect Adaptation' technology suppresses stochastic fluctuations while maintaining stable average behavior, with promising applications in cancer therapy and synthetic biology.
A new study from Texas A&M University reveals that circadian disruptions change the structure of mammary glands, weaken immune defenses, and fuel aggressive breast cancer. Disabling an immune checkpoint molecule called LILRB4 helps restore the immune system's ability to fight back.
A new study by researchers from the Germans Trias i Pujol Research Institute provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer. The review highlights molecular, cellular, and tumour microenvironment factors that explain the therapeutic dichotomy between the two tumour types.
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers at UT Health San Antonio are developing APOBEC inhibitors to block tumor mutation rates and slow cancer's evolution. The goal is to strengthen current therapies and improve their long-term effectiveness.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at IIT identified a candidate molecule called Apt1 that enhances existing anticancer therapies by making tumour cells more vulnerable to chemotherapy drugs. The molecule slows DNA repair and impairs the interaction between RAD51 and BRCA2 proteins, inducing synthetic lethality in cancerous cells.
Researchers at EPFL have developed two bioengineering approaches that exploit extracellular vesicles to train dendritic cells to identify cancer cells without the need for tumor material. The approaches, published in Nature Communications and Science Translational Medicine, show promising results in enhancing cancer immunotherapy.
Researchers at Rockefeller University discovered that the T cell receptor springs open when activated by an antigen, contrary to previous studies. This finding could lead to next-generation treatments for a broader group of cancer patients.
Researchers at the University of Geneva have created a laboratory platform to rapidly evaluate the toxicity of new cancer treatments using human tissue-derived cell clusters. This approach allows for safer evaluation and could lead to personalized treatment options.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers at UT Health Sciences Center have developed an AI-enhanced platform called ENRICH, which leverages advanced analytics with community-based human support to reduce treatment interruptions and improve cancer outcomes. The program identifies patients at highest risk for interruption and deploys targeted support resources.
Maher El-Kady's work on sustainable energy storage technologies aims to create a cleaner, more accessible future. Dr. Dennis Slamon's breakthroughs in breast cancer treatment have benefited millions worldwide, highlighting the impact of UCLA researchers on global health and innovation.
Researchers have found that CAR T-cell therapy with cilta-cel leads to higher rates of complete remission and longer progression-free survival compared to ide-cel. Treatment success is linked to factors such as tumour burden, T-cell fitness, and systemic inflammation.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
Veterans and first responders face elevated risk of cancer due to occupational exposures, such as firefighting. Experts call for better access to high-quality cancer prevention, screening, and treatment, including presumptive laws and expanded support services.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
A study finds that most people trust doctors more than AI for health diagnoses, but have a positive view of AI's potential in cancer diagnosis. The research used two nationally representative surveys to assess public attitudes toward AI in healthcare, including trust, understanding, and excitement.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
A new study by Mayo Clinic researchers found that using digital check-ins and a remote care team can help patients manage symptoms before they reach a crisis point. The trial showed that the automated surveys and responses built into the electronic health record made care more efficient and improved patients' symptoms.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
A study published in JAMA Oncology found that shorter courses of androgen deprivation therapy can effectively control prostate cancer without increasing risks. The ideal duration of ADT depends on cancer risk, allowing for more personalized treatment plans.
Researchers developed a model using DNA methylation biomarkers and CT imaging to predict lymph node metastasis in early-stage gastric cancer patients. The tool helped reduce unnecessary invasive surgeries by up to 44%.
Researchers discover IRE1α pathway in immune cells triggers inflammation and nerve damage after chemotherapy, providing a potential target for prevention and treatment. Biomarkers may help identify patients at risk of developing chemotherapy-induced peripheral neuropathy.
A microRNA cocktail has been developed to weaken glioblastoma, a type of aggressive brain tumor. The formulation, comprising 11 different non-coding RNAs, slows the growth of cancer cells and enhances chemotherapeutic drug activity.
Lung cancer screening has the potential to prevent 3 times more deaths and gain 3 times more life-years than current levels. Increasing awareness and accessibility of lung cancer screening could lead to wider adoption.
Researchers at UC San Diego found that cancer cells use non-genetic mechanisms to regrow after targeted therapy, which could help prevent tumor recurrence. By blocking these signaling pathways, future treatments may be able to stop tumors from relapsing during therapy.
The new department will drive the next generation of discovery and patient-centered care through advanced imaging and therapy. Key collaborations include UCLA Health, David Geffen School of Medicine, and UCLA Health Jonsson Comprehensive Cancer Center.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for gastric cancer. The guidelines provide evidence-based recommendations for the role of radiation therapy in multidisciplinary care, including patient selection, integration with systemic therapy and treatment delivery.
Researchers at UC San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), employing an antibody-drug conjugate to deliver chemotherapy directly into cancer cells. Targeting tumor-initiating cells through FZD7 may offer a path forward for patients with aggressive TNBC that fails to ...
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
A new bio-heterojunction platform integrates electrogenic bacteria with piezoelectric nanoparticles to eradicate colorectal tumors and restore the gut microbiome. The platform induces two distinct forms of tumor cell death, apoptosis and pyroptosis, and effectively remolds the tumor microenvironment.
LD-110, a potent LSD1 PROTAC degrader, induces ER stress and apoptosis in cancer cells by degrading LSD1 and increasing H3K4me2 levels. This study reports the discovery of LD-110 as a highly effective therapeutic agent with potential synergistic effects when combined with GSPT1 degraders.
Lymphomas develop resistance to targeted therapies through various mechanisms, including loss of target antigens, reactivation of growth pathways, and changes in tumor microenvironment. Researchers explore new treatment approaches, such as dual-target therapies and biomarker-guided therapy, to overcome these challenges.
ADCs use targeted antibodies to deliver cytotoxic payloads directly into cancer cells, destroying tumors while minimizing harm to healthy cells. Two ADCs have been approved by the FDA for gynecological cancer treatment, and numerous others are in clinical trials.
A team of researchers led by Dr. Michele Ardolino is bridging scientific fields to unlock the mechanisms behind effective immune responses in cancer patients. They will study the interactions between the immune system, nervous system, and gut microbiome to design more personalized treatment strategies.
The institute has opened its first specialized angiography-CT suite, integrating two forms of imaging equipment in one dedicated space. This allows interventional radiologists to perform both angiography and CT scans on the same day, reducing travel burdens for patients and improving treatment outcomes.
A national quality improvement program led by the American College of Surgeons found that providing structured support to cancer patients can reduce missed radiation appointments by up to 40%. The study, involving over 90,000 cancer patients, identified transportation barriers and illness as top reasons for missed appointments.
Researchers discovered that pancreatic tumors form pseudosynapses, exploiting the body's nervous system to drive tumor growth. Calcium waves triggered by glutamate binding promote metastasis and cancer progression.
Researchers studied MALAT1 levels in a woman with triple-negative breast cancer, finding high levels at diagnosis and decreased while receiving treatment. Notably, levels increased at a distant metastatic site, suggesting MALAT1's role in TNBC's spread. The study informs future treatments and potential clinical trials.
A clinical trial led by the University of Oklahoma Health Stephenson Cancer Center has shown promising results with a new drug combination targeting metastatic colorectal cancer in patients with ATM-deficient tumors. The treatment, combining alnodesertib and irinotecan, showed substantial reductions in cancer size in these patients.
A new study from the University of South Australia found that up to 50% of patients are missing out on vital foot care after chemotherapy, despite irreversible nerve damage being a common side effect. Podiatry services can prevent falls, ulcerations, pain, and improve mobility in cancer survivors with CIPN.
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.